NCT02892318View on ClinicalTrials.gov

A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML)

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

December 12, 2019

Study Completion Date

December 12, 2019

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Atezolizumab

Atezolizumab 840 mg administered by IV infusion on Days 8 and 22 of each 28-day cycle.

DRUG

Guadecitabine

Guadecitabine 60 mg/m\^2 SC on Days 1-5 of every 28-day cycle.

Trial Locations (8)

10032

The NewYork-Presbyterian Hospital Columbia University Medical Center, New York

10065

Memorial Sloan Kettering Cancer Center, New York

19140

Temple University Hospital, Philadelphia

28204

Levine Cancer Institute, Charlotte

53705

The University of Wisconsin School of Medicine and Public Health, Madison

84112

Huntsman Cancer Institute, Salt Lake City

91010

City of Hope, Duarte

06511

Yale University, New Haven

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02892318 - A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML) | Biotech Hunter | Biotech Hunter